The immunomodulatory effects of niraparib in the human tumor microenvironment were further evaluated in the niraparib-sensitive (Fig. 1E) BRCA1 mutant MDA-MB-436 TNBC tumors established in humanized NOG-EXL mice. Here, BRCA1 is linked to neoplasm.